Premium
Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma
Author(s) -
MuellerGaertner HansWilhelm,
Brzac Hanna Tomic,
Rehpenning Wolfgang
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910401)67:7<1903::aid-cncr2820670715>3.0.co;2-z
Subject(s) - medicine , thyroid cancer , risk factor , thyroid , oncology , radiation therapy , relative risk , thyroid carcinoma , cancer , follicular phase , confidence interval
Abstract To establish an objective basis for therapeutic decisions and follow‐up programs in patients with follicular thyroid cancer, the authors developed a prognostic scoring system. The prognostic impact of nine clinical, histologic, and therapeutic parameters was quantified retrospectively based on a multivariate analysis covering 149 patients. The relative relapse risk in follicular thyroid cancer (RR) was 6.8‐fold increased in the presence of a moderate when compared with a high degree of histologic tumor differentiation. The RR rose with increasing age of the patient at time of tumor diagnosis by a factor of 1.8 per 20 years. The RR was reduced by a factor of 4.3 after the performance of a neck dissection and by a factor of 2.3 after percutaneous radiation therapy of the neck. The relative mortality risk in follicular thyroid cancer (RM) rose in the absence of a tumor capsule by a factor of 10, in the presence of a moderate compared with a high degree of histologic tumor differentiation by a factor of 5.9, in the presence of distant metastases by a factor of 3.2, and with increasing age of the patient at the time of tumor diagnosis by a factor of 2.2 per 20 years. From these data prognostic indices denoting the individual risk for tumor relapse (IRR index) and tumor mortality (IMR index) were calculated. The indices categorize patients into low‐risk, medium‐risk, or high‐risk groups with regard to tumor relapse and tumor‐related death. Consequently, the IRR and IMR indices contribute to select patients with follicular thyroid cancer who need an aggressive form of treatment and an intensive follow‐up program. The indices may also be used for risk stratification in prospective therapy trials.